Compare · BIAF vs MEDP
BIAF vs MEDP
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $13.08B, about 1816.9x BIAF ($7.2M).
- Over the past year, BIAF is down 81.3% and MEDP is up 53.6% - MEDP leads by 134.9 points.
- MEDP has been more active in the news (10 items in the past 4 weeks vs 5 for BIAF).
- MEDP has more recent analyst coverage (25 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- Medpace Holdings Inc.
- Price
- $1.62-5.81%
- $457.81+0.76%
- Market cap
- $7.2M
- $13.08B
- 1M return
- -23.58%
- +6.68%
- 1Y return
- -81.28%
- +53.60%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2016
- News (4w)
- 5
- 10
- Recent ratings
- 0
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies' Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
- SEC Form S-8 filed by bioAffinity Technologies Inc.
- SEC Form 424B3 filed by bioAffinity Technologies Inc.
- SEC Form EFFECT filed by bioAffinity Technologies Inc.
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
- bioAffinity Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest MEDP
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.
- SEC Form 4 filed by Director Zander Dani S.
- SEC Form 4 filed by Director Mccarthy Cornelius P. Iii
- SEC Form 4 filed by Director Kraft Robert O.
- SEC Form 4 filed by Director Gwadry-Sridhar Femida H.
- SEC Form 4 filed by Director Davenport Fred B Jr
- SEC Form 4 filed by Director Carley Brian T